Intra-host emergence of an enterovirus A71 variant with enhanced PSGL1 usage and neurovirulence

Liang Sun, Aloys Tijsma, Carmen Mirabelli, Jim Baggen, Maryam Wahedi, David Franco, Armando De Palma, Pieter Leyssen, Erik Verbeken, Frank J. M. van Kuppeveld, Johan Neyts & Hendrik Jan Thibaut

To cite this article: Liang Sun, Aloys Tijsma, Carmen Mirabelli, Jim Baggen, Maryam Wahedi, David Franco, Armando De Palma, Pieter Leyssen, Erik Verbeken, Frank J. M. van Kuppeveld, Johan Neyts & Hendrik Jan Thibaut (2019) Intra-host emergence of an enterovirus A71 variant with enhanced PSGL1 usage and neurovirulence, Emerging Microbes & Infections, 8:1, 1076-1085, DOI: 10.1080/22221751.2019.1644142

To link to this article: https://doi.org/10.1080/22221751.2019.1644142

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd

Published online: 24 Jul 2019.

Article views: 300

View Crossmark data

View supplementary material

Submit your article to this journal

View related articles
Intra-host emergence of an enterovirus A71 variant with enhanced PSGL1 usage and neurovirulence

Liang Sun, Aloys Tijssma, Carmen Mirabelli, Jim Baggen, Maryam Wahedi, David Franco, Armando De Palma, Pieter Leyssen, Erik Verbeken, Frank J. M. van Kuppeveld, Johan Neyts and Hendrik Jan Thibaut

*These authors contributed equally to this work.

ABSTRACT

Enterovirus A71 (EV-A71) is one of the main causative agents of hand-foot-and-mouth disease and is occasionally associated with severe neurological complications. EV-A71 pathophysiology is poorly understood due to the lack of small animal models that robustly support viral replication in relevant organs/tissues. Here, we show that adult severe combined immune-deficient (SCID) mice can serve as an EV-A71 infection model to study neurotropic determinants and viral tropism. Mice inoculated intraperitoneally with an EV-A71 clinical isolate had an initial infection of the lung compartment, followed by neuroinvasion and infection of (motor)neurons, resulting in slowly progressing paralysis of the limbs. We identified a substitution (V135I) in the capsid protein VP2 as a key requirement for neurotropism. This substitution was also present in a mouse-adapted variant, obtained by passaging the clinical isolate in the brain of one-day-old mice, and induced exclusive neuropathology and rapid paralysis, confirming its role in neurotropism. Finally, we showed that this residue enhances the capacity of EV-A71 to use mouse PSGL1 for viral entry. Our data reveal that EV-A71 initially disseminates to the lung and identify viral and host determinants that define the neurotropic character of EV-A71, pointing to a hitherto understudied role of PSGL1 in EV-A71 tropism and neuropathology.

ARTICLE HISTORY

Received 13 February 2019; Revised 26 June 2019; Accepted 11 July 2019

KEYWORDS

Enterovirus A71; SCID; mouse model; CNS; tropism; pathogenesis; receptor

Introduction

Enterovirus A71 (EV-A71) belongs to the family of the Picornaviridae and is, together with Coxsackie A viruses, the main causative agent of hand-foot-and-mouth disease (HFMD), which generally affects children below the age of five. EV-A71 is currently comprised of seven genogroups (A-G), each consisting of several subgenotypes. Although EV-A71 usually causes mild and self-limiting disease, several severe and life-threatening complications such as brain stem encephalitis, meningitis, poliomylitis-like paralysis and pulmonary oedema may also occur [1,2]. EV-A71 mainly causes large HFMD outbreaks in the Asia-Pacific Region [3–5], but the incidence of EV-A71 outbreaks in Europe is increasing [6,7], which is attributed to the rapid emergence of new subgenotypes [8]. Owing to its pandemic potential and the lack of effective antiviral treatments, EV-A71 can be considered a global health threat, especially for young children. To date, two inactivated EV-A71 vaccines have been developed and marketed exclusively in China [9].

EV-A71 is highly contagious and is mainly transmitted via the fecal-oral route. Currently, the gastrointestinal tract is considered to be the primary site of replication. However, the evidence is accumulating that EV-A71 can also replicate in the respiratory tract and spread via respiratory droplets [8,10,11]. From these primary sites of infection, EV-A71 disseminates and infects other tissues and organs, including the central nervous system (CNS) [12]. Despite years of extensive research, determinants that contribute to the neurotropic character of EV-A71 remain ill defined. Furthermore, increasing evidence suggests a link between EV-A71-induced acute pulmonary oedema and an increase in mortality rates. Although it is currently not yet fully clear whether this pulmonary oedema is a consequence of a virus-induced inflammatory response or rather a neurogenic pulmonary oedema [13,14], evidence is accumulating...
pointing towards neurogenic involvement with acute, severe destruction of the brainstem tissue as the main contributing factor [15,16].

The viral uncoating receptor SCARB2 and various attachment factors (such as PSGL1, annexin II, DC-SIGN, nucleolin, vimentin, heparin sulphate and sialic acid) have been described to play a role in EV-A71 infection, either by increasing virus attachment or by mediating the uncoating process [17]. However, the exact mechanism by which they contribute to EV-A71-induced disease and outcome severity is still unknown. In addition, although various capsid residues have been described to play a role in determining receptor(s) usage, it remains elusive if and how they contribute to viral dissemination and pathogenesis. For example, a Gln or Gly at position 145 in VP1 has been described to be a determinant of PSGL1 binding [18] and, in epidemiological studies, it has been shown that these residues might also confer a more neurotropic phenotype to the virus [19]. However, no clear evidence on the possible involvement of PSGL1 in neuroinvasion is available so far [8].

Several EV-A71 mouse models have been reported, mostly in suckling mice [reviewed in [20]]. These mice lack a fully matured blood–brain–barrier (BBB) at this stage of development, limiting the relevance of these models for the study of neuroinvasion and the assessment of the potential protective effect of antivirals in the treatment of brain infections [21]. Moreover, in a number of these models, infection is performed by direct intracranial injection, which is cumbersome and not relevant from a clinical perspective [22,23]. In addition, in transgenic mice that express the human SCARB2 receptor, EV-A71 replicates in the CNS but not in the gastrointestinal or respiratory tracts [24]. Finally, immune-compromised adult mice (i.e. AG129 mice) have been described to be susceptible to EV-A71 infection [25], yet none of the above models have been used to systematically study the distribution and dissemination of the virus within the infected host. We here describe an EV-A71 infection model in severe combined immune-compromised SCID mice that exhibits two different courses of infection: one with a slowly progressing neurological disease following initial infection of the lung compartment, and the other one with fast and exclusive neurological involvement. This dual-course model provides a unique tool to explore tissue and cell tropism of EV-A71, the mechanism behind EV-A71 pathophysiology and in addition, to detail neurotropic determinants.

Results

A mouse-adapted EV-A71 strain (812MA) exhibits increased neurovirulence

EV-A71 strain #812 (a clinical isolate of subgenogroup C2 obtained from HFMD blisters of an infected child in the UK) was passaged five times in the brains of C57Bl6/J pups and subsequently passaged twice on RD cells to isolate a mouse-adapted (MA) neurotropic variant, EV-A71 strain #812MA (Figure 1(A)). Next, six-week-old severe combined immune-deficient (SCID) mice, which lack functional B cells and T cells, were infected with either the parental #812 strain or the mouse-adapted #812MA strain via the intraperitoneal (i.p) route. Mice were monitored daily and euthanized when paralysis of the hind limbs or >20% weight loss occurred. Mice that were inoculated with 2.4*10^5 PFU of the parental #812 strain or the #812MA strain showed a median survival of 17 and 6 days, respectively (Figure 1(B)). The outcome of disease correlated with weight loss (Figure 1(B), right).

To determine the pattern of tissue tropism of EV-A71 #812MA, SCID mice were inoculated with 2.4*10^5 PFU and sacrificed when signs of paralysis became apparent (median survival of 6 days) (Figure 1(C)). Subsequently, total RNA was isolated from ten different tissues and viral RNA levels were determined by means of RT-qPCR. In infected/paralysed mice, high RNA levels were detectable in the brain and spinal cord (on average 3.6*10^6 and 1.0*10^6 viral RNA copies per mg tissue respectively) as compared to other tissues. In parallel, also α/β and γ IFN receptor-deficient AG129 mice were infected with the same #812MA inoculum (Suppl. Fig. 1). In contrast to SCID mice, infected/paralysed AG129 mice showed a non-restricted systemic infection with high viral loads in almost all organs, which is less reminiscent of the natural tropism of EV-A71 in humans suggesting that SCID mice may represent a more valuable model than AG129 mice to study tissue tropism of EV-A71. Next, we determined the tissue tropism of the parental #812 strain when signs of paralysis became apparent (median survival of 17 days) (Figure 1(D)). Interestingly, infection with the parental strain revealed a more dispersed tissue tropism than #812MA, showing not only high viral RNA levels in the brain and spinal cord, but also in other organs such as lung and heart tissue (5/5 mice). To compare the pathogenesis without the bias of a longer viral persistence in the system, we also determined the tissue distribution of #812 at day 6, the day of euthanasia for most of the #812MA-infected mice (no neurological symptoms were observed at that time) (Figure 1(E)). Interestingly, high viral RNA levels were only observed in the lungs (on average 2.1*10^5 per mg tissue), whereas viral RNA could only be detected in the brain and spinal cord of one mouse. Together, these data indicate that the tissue tropism in SCID mice differs dramatically between EV-A71 strains #812MA and #812. The lung compartment is most likely the primary site of...
replication of #812 following intra-peritoneal inoculation, whereas #812MA exhibits an exclusive neurotropism.

Amino acid I135 in the VP2 “puff” loop is critical for neurotropism in mice

To find genetic determinants of the neurotropic phenotype, we fully sequenced EV-A71 #812MA and #812 genomes isolated from the respective virus stock (inoculum) and selected organs (lung, brain and spinal cord). Only one mutation was identified in the inoculum of #812MA, at position 135 in the surface-exposed highly variable EF-loop (residues 128–148, also called the “puff”) of structural protein VP2 (Table 1, Figure 2(A)). In particular, #812 carried a valine (Val135) at this position, whereas #812MA carried an isoleucine (Ile135). Virus isolated from the brains and spinal cords of all #812MA-infected mice carried VP2 Ile135 (5/5 mice). Strikingly, VP2 Ile135 was already present in virus isolated from the brains and spinal cords of one #812-infected mouse prior to the onset of neurological symptoms (day 6) and in five #812-infected mice (5/5 mice) at the day of paralysis. In contrast, the virus isolated from the lung compartment of #812-infected mice all carried VP2 Val135 at day 6 (5/5 mice) and was present in almost all mice at the day of paralysis (4/5 mice) (Table 1). These results strongly suggest that, by acquiring VP2 Ile135, the virus adopts the ability to spread to and replicate in neuronal tissues. To address whether the acquisition of VP2 Ile135 results from a host adaptation and/or tissue adaptation, we passaged the #812 strain (VP2 Val135) in various human (including RD and two neuroblastoma cell lines) and mouse cell lines (including L929 fibroblasts and N2a neuroblastoma cells). Interestingly, following replication in N2a cells, #812 acquired VP2 Ile135 as a minority variant by passage 3 and as an established substitution by passage 8 (Figure 2(B)). In contrast, passaging of #812 in all other human and mouse non-neuronal cell lines did not result in amino acid changes (Suppl. Fig. 2), suggesting that VP2 Ile135 results from both host and a tissue adaptation. In addition, #812MA exhibited a moderate replication advantage in N2a cells as compared to #812 (Figure 2(C)). Altogether, these data suggest that one amino acid change at position 135 of VP2 is necessary and sufficient for the virus to replicate in the central nervous system (CNS) of SCID mice.

Table 1. VP2 amino acid substitutions in EV-A71 #812 and #812MA.

| Virus | Paralysis | Day 6 |
|-------|-----------|-------|
| Inoculum | I135 | V135 | V135 |
| Brain | I135 (5/5) | I135 (5/5) | I135 (1/5) |
| Spinal cord | I135 (5/5) | I135 (5/5) | I135 (1/5) |
| Lung | I135 (5/5) | I135 (3/5) | V135 (5/5) |
| | V135 + M149 (1/5) |

Amino acid substitutions in VP2, compared to the inoculum of EV-A71 #812 and #812MA are indicated. The ratio of samples positive for the particular amino acid over the total number of samples is indicated between brackets.
(Motor)neurons and type II pneumocytes are two possible cell targets for EV-A71

The development of a model with a complex pathophysiology during infection prompted us to investigate the specific cell tropism of both EV-A71 #812MA and the parental EV-A71 #812 in different infected tissues by means of immunohistochemistry (IHC). In the CNS of infected mice with signs of paralysis (median day 6 p.i. for #812MA and day 17 p.i. for #812), viral antigens were detected in neurons (Figure 3(A–F)). More specifically, in the brain, mainly neurons of the cerebellum stained positive (Figure 3(A–C)) whereas in the spinal cord, viral antigens were exclusively detected in motor neurons (Figure 3(D–F)). This is in line with the pathophysiology reported in EV-A71 infected individuals with neurological complications. Other cells of the CNS such as glia cells did not stain for viral antigens. No viral antigens were detected in liver, kidney, muscle, heart, or spleen, whereas viral antigens were observed in the exocrine compartment of the pancreas and in the intestines of one mouse (Suppl. Fig. 3A). In parallel, H&E staining on brain and lung tissue of #812 and #812MA-infected mice revealed no clear evidence of virus-induced lesions or infiltration of immune cells (Suppl. Fig. 3B).

Intriguingly, IHC analysis on the lungs of #812-infected SCID mice revealed the presence of EV-A71 antigens in type II pneumocytes as well as in alveolar macrophages (Figure 3(G–I)) again pointing to a possible involvement of the lung compartment in supporting EV-A71 #812 replication. To investigate whether macrophages support EV-A71 #812 replication, various murine and human macrophages cell lines (Suppl. Fig. 4A) and murine bone-marrow-derived macrophages (Figure 3(J–K)) were infected with #812 and #812MA. None of these cell types could support the replication of either EV-A71 #812 or EV-A71 #812MA as assessed by RT-qPCR (Figure 3(J)) and end-point titration (Figure 3(K) and Suppl. Fig. 4A). Thus, our data suggest that macrophages do not support initial EV-A71 replication. In addition, to exclude the potential role of macrophage in neuroinvasion, mice were treated with clodronate liposomes via the intranasal and the intraperitoneal route to deplete macrophages locally and systemically. The local depletion was verified by IHC on lung tissue at 48 h post clodronate treatment (Suppl. Fig. 4B). SCID mice were concomitantly infected with EV-A71 #812 and weight and signs of paralysis were monitored. No clear differences were observed between the
macrophage-depleted or control mice (Suppl Fig. 4C), suggesting that macrophages do not play a role in virus spread to the CNS. Together, our data point towards a role of type II pneumocytes as the primary cell target of EV-A71 #812 (Val135 variant) in the murine respiratory tract.

We next assessed whether a virus-mediated destruction of the BBB may provide a possible explanation for the observed neuroinvasive character of #812MA. To this end, we compared the infection efficiency of EV-A71 #812 and #812MA in MBEC and CMEC/D3 cells, mouse and human brain endothelial cells, respectively. Interestingly, #812MA showed an increased replication efficiency (Figure 3(L) and Suppl. Fig. 5A) and induction of CPE (Suppl. Fig. 5B) as compared to #812 in MBEC cells, but not in CMEC/D3 or other human neuronal cell lines. In parallel, we also tested the susceptibility of human endothelial cells derived from the umbilical cord. No replication advantage of #812MA as compared to #812 could be observed (Suppl. Fig. 5A). Together, our data demonstrate that the neuropathology induced by #812MA (Ile135 variant) might be a consequence of replication in (motor) neurons and that the virus might invade the CNS by direct infection and more extensive destruction of the BBB.

Substitution V135I enhances PSGL1 usage by mouse-adapted EV-A71

As receptors are often important determinants of tropism and pathogenesis, we next assessed the levels of the two main EV-A71 receptors, SCARB2 and PSGL1, in different tissues. Gene expression levels were determined by means of RT-qPCR (Figure 4(A–B)) and protein expression was visualized by means of IHC (Figure 4(C)). The SCARB2 gene was found to be evenly expressed in all tissues (Figure 4(A)) whereas for PSGL1 a more variable gene expression profile was observed with higher levels in the lung, CNS, pancreas and spleen (Figure 4(B)). At a cellular level, the SCARB2 protein was mainly expressed on motor neurons of the CNS, the epithelial cells of the intestine, the islets and exocrine cells of the pancreas and liver Kupffer cells (Figure 4(C)). In lungs, both SCARB2 and PSGL1 antigen were found in type II pneumocytes and/or macrophages. These data further corroborate the hypothesis that motor neurons in the CNS and type II pneumocytes in the lung are the target cells for EV-A71 infection.

To investigate a possible involvement of mouse SCARB2 and PSGL1 during entry of EV-A71 #812 and #812MA, mouse PSGL1 and SCARB2 expression plasmids were transiently overexpressed in poorly permissive L929 cells, followed by EV-A71 #812 or #812MA infection. Overexpression of mPSGL1, but not mSCARB2, greatly increased virus particle attachment of both #812 and #812MA to L929 cells (Figure 4(D)). In addition, despite comparable virus input (as determined on RD cells, in which Ile135 does not enhance infection), #812MA proved to be more infectious than #812 in L929 cells overexpressing mPSGL1, as shown by an increased infectious virus production (Figure 4(E)) and dsRNA staining (Figure 4(F)).

Figure 3. EV-A71 infects (motor)neurons and type II pneumocytes. EV-A71 antigen expression in SCID mouse tissue. Mice were either mock infected or infected with EV-A71 #812MA or EV-A71 #812 and sacrificed when paralysis was first observed. Paraffin embedded, formalin fixed tissue sections were stained with an anti-EV-A71 antibody. Representative pictures of (A–C) cerebrum, (D–F) spinal cord and (G–I) lungs. (J–K) Infection of bone-marrow-derived macrophages. Cells were differentiated in M-CSF-containing medium for 6 days and infected with #812 and #812MA (MOI = 1). At selected times p.i., cells were harvested. Infection was quantified by RT-qPCR (J) and TCID₅₀ determination on RD cells (K). (L) MBEC and RD cells were infected with EV-A71 #812 or EV-A71 #812MA for 1 h. Following fresh medium replacement, the cells were further incubated for the indicated times. After fixation, the infected or mock cells were stained by dsRNA antibody, followed by high-content imaging counting. Images shown are representative fluorescent micrographs. The data shown are mean ± SEM of one (J–K) or two (L) independent experiments each containing three (J–K) to six (L) biological replicates.
the contrary, no replication advantage was noted in L929 cells overexpressing mSCARB2 (Figure 4(E–F)), despite successful transfection (Suppl Fig. 6A). Interestingly, both viruses showed comparable replication kinetics in L929 cells expressing hSCARB2 and hPSGL1 (Suppl Fig. 6B), showing that the adaptation of #7812MA to mPSGL1 did not affect the usage of hPSGL1. Finally, to explore whether mouse PSGL1 also plays a role in infection of MBEC cells we performed neutralization experiments using an anti-mouse PSGL1 antibody. The antibody was however not able to neutralize #812, #812MA and the negative control mengovirus (Suppl Fig. 6A). Altogether, these results reveal that the amino acid change Ile\textsuperscript{135} in VP2 leads to an enhanced usage of mPSGL1 and support the hypothesis that mPSGL1 might play a role in defining tissue tropism in our mouse model.

Discussion

Progress in understanding EV-A71 induced pathogenesis has been hampered by the lack of reliable small animal infection models with a relevant pathophysiology. We here established an EV-A71 infection model in SCID mice to study the dynamic distribution and tissue tropism of an EV-A71 clinical isolate. Using this model, we identified that EV-A71 initially disseminates to the lungs and showed that by acquiring a single residue mutation in the viral capsid the virus adopts the capacity to spread to and infect the CNS thereby
causing neurological disease. This restricted tissue tropism of EV-A71 in SCID mice is in sheer contrast with the non-restricted infection that we and others observed in AG129 mice. These results corroborate previous findings on the importance of type I and III IFN innate defence to restrict EV-A71 infection [25,26]. Similarly, it has been shown previously for poliovirus that unequal IFN responses define tropism and pathogenicity [27]. In addition, the complex pathophysiology as well as the straightforward readout makes this a very useful platform to assess the in vivo efficacy of novel antiviral strategies.

EV-A71 antigens were detected in (motor) neurons of the spinal cord and the cerebellum in all paralysed mice. This observation is a specific trait of neuronal EV-A71 infections in humans and may explain why EV-A71 can cause paralysis and balancing problems. It is currently unclear how EV-A71 bypasses the BBB to infect the CNS. A number of studies suggest that EV-A71 either hijacks leukocytes to pass the BBB or infects the CNS via retrograde axonal transport [28,29]. Our data suggest a model in which EV-A71 enters the mouse brain by directly destroying endothelial cells and inducing leakage of the BBB. Furthermore, we showed that EV-A71 initially infects the lungs, and more specifically type II pneumocytes, after which the virus disseminates to the CNS. This slowly progressing neuropathology following initial infection of the lung supports the current idea that, in humans, EV-A71 initially replicates in the lungs and from there disseminates systemically and infects other organs [8,10,11]. Our small animal model could thus constitute an invaluable tool for future studies to gain more insights into virus dynamics and to fully characterize determinants that allow infection of the lung and CNS.

A key determinant of virus tropism and the associated pathogenesis is the distribution of its cognate receptors in different tissues. Human SCARB2 was shown to be a functional EV-A71 uncoating receptor and transgenic mice expressing hSCARB2 develop similar pathological features as humans [17]. In contrast, it is still unclear how PSGL1 supports EV-A71 infection as transgenic mice expressing hPSGL1 were not susceptible to EV-A71 infection [24,30]. We identified a single residue (Ile\textsuperscript{135}) in VP2 that enhances the usage of mPSGL1 and that increases the neurotropic character of EV-A71. This mutant was previously described to develop as a consequence of host adaptation in murine fibroblast cells, but this only after a minimum of 60 passages [31]. However, in our hands, the Ile\textsuperscript{135} VP2 variant was in a murine neuroblastoma cell line already selected after 8 passages. This was not the case in various human cell lines or a non-neuronal murine line. This suggests that this variant is preferably selected in neuronal tissue and further underscores the possible involvement of Ile\textsuperscript{135} VP2 in the neurotropism of EV-A71 in the murine host.
and #812MA infection of susceptible MBEC cells can likely be explained by the fact that these antibodies do not bind to the epitopes that interact with the virus. An alternative explanation may be that the infection of MBEC cells occurs via alternative mechanisms that do not involve the usage of mouse PSGL1.

Altogether, this study provides not only novel insights into the mechanism underlying neurotropism, neurovirulence and dissemination of EV-A71 but also offers an invaluable tool to study the in vivo efficacy of antivirals thereby accelerating the development of antiviral therapies against this important pathogen.

Materials and methods

Cells, viruses and reagents

Human rhabdomyosarcoma (RD) cells, human neuroblastoma (SK-N-SH, SH-SY5Y) cells, murine neuroblastoma (N2a), murine cells fibroblast (L929), murine macrophage (RAW264), murine brain endothelial (MBEC) cells, murine Lewis lung carcinoma (LCC) cells were maintained in DMEM (Gibco) supplemented with 10% heat-inactivated foetal bovine serum (FBS), 1% sodium bicarbonate (Gibco) and 1% L-glutamine (Gibco). L929-hSCARB2 cells and L929-hPSGL1 cells are kindly provided by Prof. S. Liekens and Dr. M. Benkheil and were maintained in EBM-2 medium supplemented with 1 ng/ml human basic fibroblast growth factor, 10 mm HEPES, 1% chemically defined lipid concentrate, 5 μg/ml ascorbic acid, 1.4 μM hydrocortisone, 1% pen–streptomycin and 5% of heat-inactivated FBS. EV-A71 strain H08300 461 (#812) of sub-genogroup C2 was obtained from European Virus Archive and was isolated from HFMD blisters of an infected-child in UK. EV-A71 #812MA (Mouse Adapted variant) was obtained during this study. EV-A71 BrCr strain, was obtained from the National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands. EMCV strain Mengo was a kind gift from Prof. T. Michiels (de Duve Institute, Université catholique de Louvain, Belgium). For in vitro assays the medium used was supplemented with 2% FBS. Mouse SCARB2 and PSGL1 cDNA clone expression plasmids containing a signal peptide and anti-mouse PSGL1 antibody (50770-RP01) were purchased from Bio-connect.

Mouse adaptation of EV-A71 #812

All experiments were performed according to the university guidelines for animal care and are approved by the ethical committee of the University of Leuven. One-day-old C57Bl6/J mice were intracranially (i.c.) infected with 20 μl of EV-A71 #812. Two days p.i., mice were euthanized, brain tissue was collected and homogenized and it was used to infect naïve one-day-old C57Bl6/J i.c. The experiment was repeated five times (five passages) and 100 μl of the P5 homogenate was used to infect RD cells. After two passages in RD cells, a viral stock was harvested and used for the following experiment EV-A71 #812MA.

Mouse infection studies and tissue collection

SCID mice (in-house bred) were housed in individual ventilated cages. Mice were intraperitoneally (i.p.) injected with EV-A71 #812 or EV-A71 #812MA at an indicated concentration (PFU/mouse). Limb paralysis and/or >20% weight loss were used as a criterion for early euthanasia by Nembutal injection. After euthanasia and extensive perfusion with PBS, indicated organs/tissues were collected. Each organ/tissue sample was cut in half; one half was frozen in liquid nitrogen for subsequent viral RNA isolation and the other half was fixed with 4% formaldehyde for immunohistochemistry.

Viral RNA isolation and RT-qPCR

Frozen tissues were homogenized in lysis buffer using a Precellys 24 homogenizer. After centrifugation of the homogenates, the supernatants were used for RNA isolation (Qiagen RNeasy). Viral RNA load in the tissues was quantified by means of RT-qPCR using the One-step RT-qPCR MasterMix Low ROX (Eurogentec) in a Lightcycler 96 (Roche). A serial dilution of synthetic DNA (gBlocks, IDT) corresponding to the sequence/size of the amplicon was used to build a standard curve. For the expression of PSGL1 and SCARB2 relative gene expression was calculated using the 2^-ΔΔCt method [20]. β-actin was used as internal control.

Serial passaging

EV-A71 #812 and EV-A71 #812MA were used to infect N2a, L929, RD, SK-N-SH and SH-SY5Y cells (MOI = 1). Following 1 h infection at 37°C and a PBS washing step, cells were further incubated for three days. The infected cell cultures were freeze/thawed twice. For all subsequent rounds of infection in the virus was 1/5 diluted.

Histology

Formalin fixed, paraffin embedded tissue sections were deparaffinized using Bond Dewax Solution (Leica) after which Epitopes were retrieved using Bond Epitope Retrieval Solution 1 (Leica). The sections were stained for EV-A71 antigen (10F0, abcam), PSGL1 (bs-0561R, Bioss) or SCARB2 (NB400-129, Novus). In addition,
haematoxylin and eosin staining was performed to visualize inflammation.

**Macrophage isolation**
Bone marrow from the femur of two SCID mice was collected. Cells were filtrated and kept on ice. A suspension of $2 \times 10^6$ cells/ml was prepared in differentiation medium: RPMI, 10% FBS, 1X non-essential amino acids, sodium pyruvate, PenStrep and 20 ng/ml of M-CSF. On day 1, 3, and 6, the medium was refreshed with pre-warmed new differentiation medium. On day 7, macrophages were fully differentiated and ready for infection (MOI = 1). At indicated times p.i. the supernatant from infected-macrophages was used to determine viral titres by end-point titration on RD cells. Viral RNA was obtained after extraction of total RNA from infected-macrophages at indicated times p.i. and quantified by RT-qPCR.

**Macrophage depletion in vivo**
To allow the specific depletion of macrophages in the lung compartment, SCID mice were treated with 200 µl of clodronate liposomes or PBS liposomes: 100 µl were injected intraperitoneally (i.p.) and 100 µl were administered intranasally after anaesthesia (xylazine/ketamine). Concomitantly, mice were infected with $10^6$ PFU of EV-A71 #812 i.p. Macrophage depletion from the lung compartment was confirmed by immunohistochemistry (two days post clodronate treatment). Infected mice were monitored daily for the sign of disease and euthanasia was administered whenever 20% of weight loss or paralysis of the limbs was observed.

**Infectivity and immunofluorescence assays**
Cells were infected with virus for 1 h at 37°C, followed by a PBS washing step. Cells were supplied with fresh medium, and incubated for the indicated time-points. For infectivity assays, cells were subjected to freeze/thaw cycles and viral titres were determined by endpoint dilution on RD cells. For immunofluorescence assays, cells were fixed by 3.7% paraformaldehyde for 15 min at room temperature. Fixed cells were stained by 1:500 diluted anti-dsRNA monoclonal antibody (J2, SCICONS). The number of infected cells were examined and quantified by high-content imaging.

**Acknowledgments**
We appreciate the excellent technical assistance of Jasmine Paulissen.

**Disclosure statement**
No potential conflict of interest was reported by the authors.

**Funding**
L.S. received funding of the China Scholarship Council (CSC) [grant number 201403250056]. Funding was provided by European Union 7th Framework Program (EUVIRNA Marie Curie Initial Training Network), grant agreement number 264286. J.N. received funding from BELSPO (Belgian Science Policy Office) [grant number IUAP-BELVIR]. F.J.M.v.K. received funding from the Netherlands Organization for Scientific Research (grant number NWO-VICI-91812628). Part of this research work was performed using the ‘Caps-It’ research infrastructure [Fonds Wetenschappelijk Onderzoek; project 2W13-02] that was financially supported by the Hercules Foundation (FWO) and Rega Foundation, KU Leuven.

**ORCID**
Jim Baggen [http://orcid.org/0000-0002-1628-6766](http://orcid.org/0000-0002-1628-6766)
Frank J. M. van Kuppeveld [http://orcid.org/0000-0001-5800-749X](http://orcid.org/0000-0001-5800-749X)
Johan Neyts [http://orcid.org/0000-0002-0033-7514](http://orcid.org/0000-0002-0033-7514)
Hendrik Jan Thibaut [http://orcid.org/0000-0001-5785-8276](http://orcid.org/0000-0001-5785-8276)

**References**
[1] Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097–1105. DOI:10.1016/S1474-4422(10)70209-X.
[2] Wong KT, Munisamy B, Ong KC, et al. The distribution of inflammation and virus in human Enterovirus 71 encephalomyelitis suggests possible viral spread by neural pathways. J Neuropathol Exp Neurol. 2008;67:162–169. DOI:10.1097/nen.0b013e318163a990.
[3] Puenpa J, Mauleekoonphairoj J, Linsuwanon P, et al. Prevalence and characterization of enterovirus infections among pediatric patients with hand foot mouth disease, herpangina and influenza like illness in Thailand, 2012. PLoS One. 2014;9:e98888. DOI:10.1371/journal.pone.0098888.
[4] Liu W, Wu S, Xiong Y, et al. Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot, and mouth disease in Central China. PLoS One. 2014;9:e96051. DOI:10.1371/journal.pone.0096051.
[5] Thoa LPK, Chiang P-S, Khanh TH, et al. Genetic and antigenic characterization of enterovirus 71 in Ho Chi Minh City, Vietnam, 2011. PLoS One. 2013;8:e98995. DOI:10.1371/journal.pone.0098985.
[6] Akhmadishina LV, Eremeeva TP, Trotsenko OE, et al. Seroepidemiology and molecular epidemiology of enterovirus 71 in Russia. PLoS One. 2014;9:e97404. DOI:10.1371/journal.pone.0097404.
[7] Fonseca MC, Sarmiento L, Resik S, et al. Coxsackievirus A6 and enterovirus 71 causing hand, foot and mouth disease in Cuba, 2011-2013. Arch Virol. 2014;159:2451–2455. DOI:10.1007/s00705-014-2071-x.
[8] Van Der Sanden SMG, Sachs N, Koekkoek SM, et al. Enterovirus 71 infection of human airway organoids reveals VP1-145 as a viral infectivity determinant article. Emerg Microbes Infect. 2018;7:1–9. DOI:10.1038/s41426-018-0077-2.
[9] Yi E-J, Shin Y-J, Kim J-H, et al. Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res. 2017;6:4. DOI:10.7774/cevr.2017.6.1.4.

[10] Tseliogke ED, Sobu K, Stoppini L, et al. A VP1 mutation acquired during an enterovirus 71 disseminated infection confers heparan sulfate binding ability and modulates ex vivo tropism. PLoS Pathog. 2018;14:e1007190. DOI:10.1371/journal.ppat.1007190.

[11] Zhang Y, Cui W, Liu L, et al. Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab Invest. 2011;91:1337–1350. DOI:10.1038/labinvest.2011.82.

[12] Royston L, Tapparel C. Rhinoviruses and respiratory enteroviruses: not as simple as ABC. Viruses. 2016;8(1):16. DOI:10.3390/v8010016.

[13] Solomon T, Lewthwaite P, Perara D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10(11):778–790. DOI:10.1016/S1473-3099(10)70194-8.

[14] Wang S, Liu C-C, Tseng H-W, et al. Clinical Spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis. 2007;29:184–190. DOI:10.1086/520149.

[15] Victorio CBL, Xu Y, Ng Q, et al. A clinically authentic mouse model of enterovirus 71 (EV-A71)-induced neurogenic pulmonary oedema. Sci Rep. 2016;6. DOI:10.1038/srep28876.

[16] Huang C-C, Liu C-C, Chang Y-C, et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med. 2002;347:396–394. DOI:10.1056/nejm200204043411302.

[17] Baggen J, Jan Thibaut H, Strating JRPM, et al. The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol. 2018;16(6):368–381.

[18] Nishimura Y, Lee H, Hafenstejn S, et al. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog. 2013;9(7):e1003511. DOI:10.1371/journal.ppat.1003511.

[19] Liu Y, Fu C, Wu S, et al. A novel finding for enterovirus virulence from the capsid protein VP1 of EV71 circulating in mainland China. Virus Genes. 2014;48:260–272. DOI:10.1007/s11262-014-1035-2.

[20] Wang Y-F, Yu C-K. Animal models of enterovirus 71 infection: applications and limitations. J Biomed Sci. 2014;21:31. DOI:10.1186/1423-0127-21-31.

[21] Marc T. Brain development and the immune system: an introduction to inflammatory and infectious diseases of the child’s brain. Handb Clin Neurol. 2013;122:1087–1089. DOI:10.1016/B978-0-444-52910-7.00026-X.

[22] Zaini Z, Phuetske P, McMinn P. Mouse adaptation of a sub-genogroup B5 strain of human enterovirus 71 is associated with a novel lysine to glutamic acid substitution at position 244 in protein VP1. Virus Res. 2012;167:86–96. DOI:10.1016/j.virusres.2012.04.009.

[23] Khong WX, Yan B, Yeo H, et al. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol. 2012;86:2121–2131. DOI:10.1128/JVI.06103-11.

[24] Fuji K, Nagata N, Sato Y, et al. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci U S A. 2013;110:14753–14758. DOI:10.1073/pnas.1217563110.

[25] Caine EA, Moncla LH, Ronderos MD, et al. A single mutation in the VP1 of enterovirus 71 is responsible for increased virulence and neurotropism in adult interferon-deficient mice. J Virol. 2016;90:8592–8604. DOI:10.1128/JVI.01370-16.

[26] Pathinayake PS, Hsu ACY, Wark PAB. Innate immunity and immune evasion by enterovirus 71. Viruses. 2015;7:6613–6630. DOI:10.3390/v7122961.

[27] Ida-Hosonuma M, Iwasaki T, Yoshikawa T, et al. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol. 2005;79:4460–4469. DOI:10.1128/JVI.79.7.4460-4469.2005.

[28] Chen C-S, Yao Y-C, Lin S-C, et al. Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J Virol. 2007;81:8996–9003. DOI:10.1128/JVI.00236-07.

[29] Koyuncu OO, Hogue IB, Enquist LW. Virus infections in the nervous system. Cell Host Microbe. 2013;13:379–393. DOI:10.1016/j.chom.2013.03.010.

[30] Liu J, Dong W, Quan X, et al. Transgenic expression of human P-selectin glycoprotein ligand-1 is not sufficient for enterovirus 71 infection in mice. Arch Virol. 2012;157:539–543. DOI:10.1007/s00705-011-1198-2.

[31] Victorio CBL, Xu Y, Ng Q, et al. Phenotypic and genotypic characteristics of novel mouse cell line (NHI/3T3)-adapted human enterovirus 71 strains (EV71: TLLm and EV71:TLLmv). PLoS One. 2014;9:e92719. DOI:10.1371/journal.pone.0092719.

[32] Jiao XY, Guo L, Huang DY, et al. Distribution of EV71 receptors SCARB2 and PSGL-1 in human tissues. Virus Res. 2014;190:40–52. DOI:10.1016/j.virusres.2014.05.007.

[33] Chen P, Song Z, Qi Y, et al. Molecular determinants of enterovirus 71 viral entry: Cleft around GLN-172 on VP1 protein interacts with variable region on scavenger receptor B 2. J Biol Chem. 2012;287:6406–6420. DOI:10.1074/jbc.M111.301622.

[34] Victorio CBL, Xu Y, Ng Q, et al. Cooperative effect of the VP1 amino acids 98E, 145A and 169F in the productive infection of mouse cell lines by enterovirus 71 (BS strain). Emerg Microbes Infect. 2016;5:1–14. DOI:10.1038/em.2016.56.

[35] Plevka P, Perera R, Yap ML, et al. Structure of human enterovirus 71 in complex with a capsid-binding inhibitor. Proc Natl Acad Sci U S A. 2013;110:5463–5467. DOI:10.1073/pnas.1223791110.

[36] Miyamura K, Nishimura Y, Abo M, et al. Adaptive mutations in the genomes of enterovirus 71 strains following infection of mouse cells expressing human P-selectin glycoprotein ligand-1. J Gen Virol. 2011;92:287–291. DOI:10.1099/vir.0.022418-0.

[37] Nishimura Y, Wakita T, Shimizu H. Tyrosine sulfation for increased virulence and neurotropism in adult interferon-deficient mice. J Virol. 2005;79:4460–4469. DOI:10.1128/JVI.79.7.4460-4469.2005.

[38] Zhou D, Zhao Y, Kotecha A, et al. Unexpected mode of engagement between enterovirus 71 and its receptor SCARB2. Nat Microbiol. 2019;4:414–419. DOI:10.1038/s41564-018-0319-z.